Clinical Trials Logo

Soft Tissue Neoplasm clinical trials

View clinical trials related to Soft Tissue Neoplasm.

Filter by:
  • None
  • Page 1

NCT ID: NCT04540588 Recruiting - Skin Cancer Clinical Trials

Retreatment With Intratumoral Diffusing Alpha Radiation Emitters

Start date: December 22, 2020
Phase: N/A
Study type: Interventional

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia

NCT ID: NCT04534127 Recruiting - Skin Cancer Clinical Trials

Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia

Start date: December 22, 2020
Phase: N/A
Study type: Interventional

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia

NCT ID: NCT04394052 Recruiting - Bone Neoplasm Clinical Trials

Novel Imaging Techniques for the Characterization of Musculoskeletal Tumors II

TUMOSTEO II
Start date: June 1, 2020
Phase:
Study type: Observational

This study aims at evaluating the value of various artificial intelligence based techniques to improve the characterization and image post-processing for patients with musculoskeletal tumors.

NCT ID: NCT03889899 Recruiting - Skin Cancer Clinical Trials

Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.

Start date: October 21, 2020
Phase: N/A
Study type: Interventional

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia

NCT ID: NCT03886181 Recruiting - Skin Cancer Clinical Trials

Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia (DaRT)

Start date: July 8, 2021
Phase: N/A
Study type: Interventional

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia

NCT ID: NCT03737734 Active, not recruiting - Skin Cancer Clinical Trials

Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia (DaRT)

Start date: December 31, 2018
Phase: N/A
Study type: Interventional

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia

NCT ID: NCT03452644 Completed - Soft Tissue Sarcoma Clinical Trials

US-Guided Biopsy in the Diagnosis of Musculoskeletal Soft-Tissue Tumors

Start date: September 20, 2018
Phase:
Study type: Observational

A retrospective evaluation of soft tissue tumors that have undergone core needle biopsy with US guidance (US-CNB)

NCT ID: NCT02775799 Terminated - Neoplasms Clinical Trials

National Swiss Sarcoma Cohort Study

SwissSARCOS
Start date: April 2015
Phase:
Study type: Observational [Patient Registry]

Registration of all sarcoma patients treated at a specialized sarcoma center in Switzerland.

NCT ID: NCT01552434 Active, not recruiting - Malignant Neoplasm Clinical Trials

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Start date: March 16, 2012
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of bevacizumab and temsirolimus alone or in combination with valproic acid or cetuximab in treating patients with a malignancy that has spread to other places in the body or other disease that is not cancerous. Immunotherapy with bevacizumab and cetuximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as valproic acid, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether bevacizumab and temsirolimus work better when given alone or with valproic acid or cetuximab in treating patients with a malignancy or other disease that is not cancerous.